Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN Podcasts

*Podcasts play in a pop-up window. Please make sure your pop-up blocker is off.

GEN’s editor in chief, John Sterling, interviews life science academic and biotech industry leaders on important research, technology, and trends. These podcasts will keep you informed with all the important details you need.

Jon J. Jonsson, M.D., Ph.D. was educated at University of Iceland Medical School. After basic postgraduate training in medicine at the University of Iceland Hospitals he trained in clinical pathology at University of Minnesota where he also received his PhD. Subsequently he trained in medical genetics at Yale University. He has been on the faculty at the University of Iceland since 1997. Currently he serves as an associate professor and chair of the Division of of Biochemistry, Clinical Biochemistry and Medical Genetics and as medical director of Dept. of Genetics and Molecular Medicine at Landspitali – University Hospital in Reykjavik, Iceland. His research group works on method development in molecular genetics. They formed a spinoff company BioCule Inc. (www.biocule.com) to commercially exploit their inventions in 2D electrophoresis of nucleic acids for biomarker discovery, quality control and validation.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »